ARCHIVES

Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

Cooperative Groups Get Reprieve From Cut As Budget Is Flatlined At Fiscal 2006 Level.

June 8, 2007

New CIDAC RFP Limits Recompetition To Small Business Firms

January 6, 1984

In Brief: Schmidt Sells OMB On Training Grants, But Weinberger Is The One To Convince

December 21, 1973

In Brief: Little Relation of Cancer Incidence To Known Carcinogens Except For Cigarettes, Holleb Says

July 14, 1978

Report Backs EPA Classification of PERC as Likely Human Carcinogen

February 12, 2010

‘Helping Smokers Quit’ Program Launched By NCI, Pharmacist Group

June 27, 1986